OCA
CRBP icon

Octagon Capital Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Octagon Capital Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-955,000
Closed -$7.77M – 32
2025
Q4 		$7.77M Sell
955,000
-160,000
-14% -$1.97M 0.94% 25
2025
Q3 		$14.1M Hold
1,115,000
– – 2.14% 17
2025
Q2 		$7.69M Hold
1,115,000
– – 1.69% 22
2025
Q1 		$5.92M Hold
1,115,000
– – 1.15% 29
2024
Q4 		$13.2M Hold
1,115,000
– – 2.17% 18
2024
Q3 		$23M Buy
1,115,000
+627,000
+128% +$32.1M 3.58% 9
2024
Q2 		$22.1M Buy
488,000
+83,000
+20% +$3.49M 3.47% 8
2024
Q1 		$15.9M Buy
+405,000
New +$9.99M 1.9% 15

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Octagon Capital Advisors's CRBP Position: Q1 2026 in Review

Octagon Capital Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q1 2026, closing a stake of 955,000 shares — an estimated $7.77M sold.

Octagon Capital Advisors first reported a position in CRBP in Q1 2024 and held it in 8 quarters. The position peaked at $23M in Q3 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Octagon Capital Advisors reported no remaining Corbus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Octagon Capital Advisors sold 955,000 Corbus Pharmaceuticals shares in Q1 2026, an estimated $7.77M.
  • Octagon Capital Advisors first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Octagon Capital Advisors's Corbus Pharmaceuticals position peaked at $23M in Q3 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.